Your Science Reps' Report Jan 2024

Clinical trials have demonstrated that a new cancer vaccine, developed by a French biotechnology company, could potentially increase survival rates for certain lung cancers by nearly fifty percent. This is particularly encouraging news, as lung cancer is the leading cause of cancer-related deaths in both Europe and the United States. The vaccine, named Tedopi, is a therapeutic cancer
vaccine, which differs from preventative vaccines. It is designed to train the immune system to recognize and eliminate tumour cells, essentially harnessing the body's own defence mechanisms to combat cancer.

The realm of immunotherapy has witnessed significant progress since the 2010s. This field has further benefited from research conducted during the pandemic, which, according to Cancer Research UK, "has accelerated the production of vaccines, specifically mRNA vaccines."

So, on a positive note, Covid and the ensuing pandemic has given us something to be grateful for!
In 2023 the government signed an agreement with BioNTech to begin cancer vaccine trials, treating up to 10,000 patients by 2030.  Innovative lung screening methods, including mobile clinics performing tests in parking lots, have identified nearly 3,000 lung cancer cases, with three-quarters of them detected at an early stage. Remarkably, the NHS has conducted urgent cancer checks for a record three million people over the past year.

The all-party parliamentary group on cancer in the UK has emphasised the necessity of matching other countries in diagnosing and treating less survivable cancers to provide world-class care. They note that the UK's cancer survival rates are among the poorest in wealthy countries.

We look forward to seeing you Tuesday 12 March 2024 in Aylesbury for the Investigation and Discovery Day for more Science & Society’s facts and figures and a chat with many of you.
Perhaps the sun will shine!